Dr. Vivek Rao, MD
Claim this profileToronto General Hospital
Studies Coronary Artery Disease
Studies Heart Disease
5 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Vivek Rao, MD is currently running
Heart Surgery
for Coronary Artery Disease
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Recruiting1 award N/A4 criteria
DOAC vs Warfarin as Blood Thinners After Heart Surgery
for undefined
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Recruiting3 awards Phase 34 criteria
More about Vivek Rao, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Vivek Rao, MD has experience with
- Multiple Arterial Grafting
- Single Arterial Graft
- Revascularization By CABG
- Revascularization By PCI
- Model 400 Aortic Valve Bioprosthesis
- DOAC
Breakdown of trials Vivek Rao, MD has run
Coronary Artery Disease
Heart Disease
Heart Failure
Left Ventricular Dysfunction
Von Willebrand Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vivek Rao, MD specialize in?
Vivek Rao, MD focuses on Coronary Artery Disease and Heart Disease. In particular, much of their work with Coronary Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Vivek Rao, MD currently recruiting for clinical trials?
Yes, Vivek Rao, MD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Vivek Rao, MD has studied deeply?
Yes, Vivek Rao, MD has studied treatments such as Multiple Arterial Grafting, Single Arterial Graft, Revascularization by CABG.
What is the best way to schedule an appointment with Vivek Rao, MD?
Apply for one of the trials that Vivek Rao, MD is conducting.
What is the office address of Vivek Rao, MD?
The office of Vivek Rao, MD is located at: Toronto General Hospital, Toronto, Ontario M5G 2N2 Canada. This is the address for their practice at the Toronto General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.